ID: ALA407109

Max Phase: Preclinical

Molecular Formula: C15H12Cl3NO2

Molecular Weight: 344.62

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cc1ccc(Nc2c(Cl)cc(Cl)cc2Cl)c(CC(=O)O)c1

Standard InChI:  InChI=1S/C15H12Cl3NO2/c1-8-2-3-13(9(4-8)5-14(20)21)19-15-11(17)6-10(16)7-12(15)18/h2-4,6-7,19H,5H2,1H3,(H,20,21)

Standard InChI Key:  UZKUKYXDPJBSFW-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 344.62

Molecular Weight (Monoisotopic): 342.9934

AlogP: 5.33

#Rotatable Bonds: 4

Polar Surface Area: 49.33

Molecular Species: ACID

HBA: 2

HBD: 2

#RO5 Violations: 1

HBA (Lipinski): 3

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 3.87

CX Basic pKa:

CX LogP: 5.38

CX LogD: 2.15

Aromatic Rings: 2

Heavy Atoms: 21

QED Weighted: 0.79

Np Likeness Score: -0.94

References

1. Blobaum AL, Marnett LJ..  (2007)  Molecular determinants for the selective inhibition of cyclooxygenase-2 by lumiracoxib.,  282  (22): [PMID:17434872] [10.1074/jbc.m609883200]

2. Windsor MA, Valk PL, Xu S, Banerjee S, Marnett LJ..  (2013)  Exploring the molecular determinants of substrate-selective inhibition of cyclooxygenase-2 by lumiracoxib.,  23  (21): [PMID:24060487] [10.1016/j.bmcl.2013.08.097]

Source

Source(1):

• Scientific Literature